All In Biotech

Drug Trial Radar · NCT06768489

A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma

A Phase 1b Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig With Pomalidomide for Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Dec 4, 2024

Primary completion

Jan 2, 2029

Study completion Jun 29, 2029

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses \[RP2Ds\]) and schedule for ramantamig treatment regimens and JNJ-102299639 treatment regimens; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of ramantamig and JNJ-102299639 treatment regimens at selected RP2D(s).

Conditions

  • Multiple Myeloma
  • Smoldering Multiple Myeloma
  • Immunoglobulin Light-chain Amyloidosis

Interventions

  • RamantamigDrug

    Ramantamig will be administered subcutaneously.

  • DaratumumabDrug

    Daratumumab will be administered subcutaneously.

  • PomalidomideDrug

    Pomalidomide will be administered orally.

  • LenalidomideDrug

    Lenalidomide will be administered orally.

  • JNJ-102299639Drug

    JNJ-102299639 will be administered subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants with Dose-limiting Toxicity (DLT)Time frame: Up to 28 days
  2. Number of Participants with Adverse Events (AEs) by SeverityTime frame: Up to 3 Years and 3 months
  3. Number of Participants with Clinically Significant Laboratory AbnormalitiesTime frame: Up to 3 Years and 3 months

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • Colorado Blood Cancer Institute

    Denver, Colorado · Recruiting

  • Winship Cancer Institute Emory University

    Atlanta, Georgia · Recruiting

  • Monash Medical Centre

    Clayton, Australia · Recruiting

  • St Vincents Hospital Melbourne

    Fitzroy, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Australia · Recruiting

  • Calvary Mater Newcastle Hospital

    Waratah, Australia · Recruiting

  • Wollongong Hospital

    Wollongong, Australia · Recruiting

  • Carmel Medical Center

    Haifa, Israel · Recruiting

  • Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • Hadassah Medical Center

    Yeruham, Israel · Recruiting

  • VU Medisch Centrum

    Amsterdam, Netherlands · Recruiting

  • Universitair Medisch Centrum Groningen

    Groningen, Netherlands · Recruiting

  • UMC Utrecht

    Utrecht, Netherlands · Recruiting

  • Hosp. Clinic de Barcelona

    Barcelona, Spain · Recruiting

  • Hosp Clinico Univ de Salamanca

    Salamanca, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.